Pharmaceuticals

By integrating cash prices directly into the EHR workflow, Epic's upcoming Prescription Marketplace challenges traditional PBMs and empowers patients.

Amidst geopolitical headwinds, WuXi XDC's double win at the 2026 World ADC Awards highlights a relentless drive to dominate the bioconjugate supply chain.

LTR Pharma’s Roxus nasal spray promises ED treatment in ten minutes. But the real disruption is how the company is using compounding laws to enter the U.S. market.

Merz completes Phase III migraine trial recruitment six months early, signaling a strategic threat to AbbVie’s dominance with its purified neurotoxin, XEOMIN.

Following a transformative $225 million capital injection, Lisata Therapeutics appoints a seasoned biotech M&A architect to its board of directors.

By halving infusion volumes for immunodeficiency patients, Takeda's experimental TAK-881 is not just treating a disease—it is giving people their time back.

Elion Therapeutics secures global rights to EL777, an inhaled antifungal aiming to prevent deadly infections in a growing immunocompromised population.

Modern medicine’s greatest triumphs in oncology and rheumatology are inadvertently fueling a silent surge in Secondary Immunodeficiencies.

By building talent infrastructure before the factories even open, Ohio is aggressively positioning the Midwest to dethrone coastal biomanufacturing hubs.

As a new foundation offers free seminars for Thyroid Eye Disease, it highlights the complex intersection of rare disease advocacy and pharmaceutical marketing.

Trevi Therapeutics heads to CHEST 2026 with compelling patient-reported outcomes for its IPF chronic cough drug, aiming to fill a massive clinical void.

Immuron’s Phase 2 Travelan trial missed its primary endpoint, but a 71% drop in antibiotic use has the Pentagon and microbiome experts paying close attention.

After a high-profile Phase 2 trial failure in pulmonary fibrosis, Syndax narrows its strategic focus to maximize its established cGVHD partnership with Incyte.

By proving IBSRELA reduces costly specialist visits, Ardelyx is arming itself for payer negotiations and a lucrative leap into the broader constipation market.

Phathom Pharmaceuticals is using predictive modeling to prove its premium-priced drug VOQUEZNA can beat generic PPIs by preventing long-term complications.

Odyssey Therapeutics is testing a novel combination therapy for ulcerative colitis, aiming to break the therapeutic ceiling that limits current IBD treatments.

The NMPA approval of a 6-month prostate cancer drug reveals how mid-tier biotechs navigate China's complex healthcare landscape via strategic partnerships.

For decades, severe acne treatments forced patients into a maze of antibiotics and harsh side effects. A new drug might finally change the system.

With new Phase 3 data for inactive thyroid eye disease, Innovent Biologics is solidifying a domestic moat against foreign biotech rivals in China.

Asahi Kasei Therapeutics begins Phase 2a trials for AIC468, a pioneering RNA-splicing therapy aiming to solve a critical kidney transplant dilemma.